Skip to content
Article Rich – Lifestyle
Author:
Reworld Holding Corporation
Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis
June 22, 2026
Reworld® Appoints Brendan Ferretti as EVP, Business Development and M&A
June 16, 2026
Reworld® Publishes 2026 Sustainability Report, Highlighting Measurable Outcomes in Waste Solutions
June 15, 2026
Reworld® Introduces ReAssure™, Providing Full-Scale Destruction Capacity for PFAS-Containing Materials
June 9, 2026
First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026
May 21, 2026
Reworld™ Drives Local Environmental Impact Through Earth Month Initiatives
May 4, 2026